CEPI partners with Bharat Biotech, University of Sydney, ExcellGene to develop 'variant-proof' COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) on Tuesday announced the latest award under its USD 200 m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other beta coronaviruses.